SITC 2021: Updates on the use of cellular therapy in solid tumors

Cellular immunotherapy approaches have proven to be highly effective in the treatment of patients with hematological malignancies over recent years. In contrast, the efficacy of cellular immunotherapy in solid tumors has been restricted due to a limited array of tumor-specific antigens to differentiate cancer cells from normal cells.  In this podcast, we spoke with three leading experts in cellular immunotherapy who delineate the methods being used to overcome the challenges faced in targeting solid. Join Julian Molina, MD, PhD, Mayo Clinic, Rochester, MN, Jeffrey S. Miller, MD, University of Minnesota, Minneapolis, MN, and Alexander Kamb, PhD, A2 Biotherapeutics, Agoura Hills, CA for a discussion of chimeric antigen receptor (CAR)-T cell approaches in the BASECAMP-1 study, pluripotent stem cell (iPSC)- derived NK cells to treat glioblastoma and the use of the Tmod™ (T-cell module) platform, which involves utilization of activating and inhibitory receptors to specifically target solid tumors.  This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.